Despite recent share price drops, Gansu Longshenrongfa Pharmaceutical's P/E is still higher than most firms. If medium-term earnings trends persist, shareholders' investments could be at risk and potential investors may pay an excessive premium.
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more